Nasrin Rastgoo

726 total citations
25 papers, 551 citations indexed

About

Nasrin Rastgoo is a scholar working on Molecular Biology, Hematology and Immunology. According to data from OpenAlex, Nasrin Rastgoo has authored 25 papers receiving a total of 551 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 8 papers in Hematology and 5 papers in Immunology. Recurrent topics in Nasrin Rastgoo's work include Multiple Myeloma Research and Treatments (6 papers), RNA Interference and Gene Delivery (4 papers) and MicroRNA in disease regulation (4 papers). Nasrin Rastgoo is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), RNA Interference and Gene Delivery (4 papers) and MicroRNA in disease regulation (4 papers). Nasrin Rastgoo collaborates with scholars based in Canada, United States and China. Nasrin Rastgoo's co-authors include Hong Chang, Rosemarie Tremblay‐LeMay, Jahangir Abdi, Hong Chang, Donna Reece, Aijun Liu, Wen-Ming Chen, Jian Hou, Wenming Chen and Lihong Li and has published in prestigious journals such as Blood, Cancer Research and Cancer Letters.

In The Last Decade

Nasrin Rastgoo

23 papers receiving 547 citations

Peers

Nasrin Rastgoo
Qing Tong China
Karel Fostier Belgium
Talía Velasco-Hernández Spain
Virginia Giuliani Italy
Srikanth Talluri United States
Felipe Vences‐Catalán United States
Dazhong Zhuang United States
Margaret Bell United Kingdom
Joydeep Bhadury Sweden
Margherita Ghisi Australia
Qing Tong China
Nasrin Rastgoo
Citations per year, relative to Nasrin Rastgoo Nasrin Rastgoo (= 1×) peers Qing Tong

Countries citing papers authored by Nasrin Rastgoo

Since Specialization
Citations

This map shows the geographic impact of Nasrin Rastgoo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nasrin Rastgoo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nasrin Rastgoo more than expected).

Fields of papers citing papers by Nasrin Rastgoo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nasrin Rastgoo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nasrin Rastgoo. The network helps show where Nasrin Rastgoo may publish in the future.

Co-authorship network of co-authors of Nasrin Rastgoo

This figure shows the co-authorship network connecting the top 25 collaborators of Nasrin Rastgoo. A scholar is included among the top collaborators of Nasrin Rastgoo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nasrin Rastgoo. Nasrin Rastgoo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rastgoo, Nasrin, Jean-François Brazeau, Kyohei Hayashi, et al.. (2025). Abstract A026: Discovery of potent and selective CDK2 molecule glue degraders for the treatment of HR+/HER2- breast cancer, and CCNE1 amplified tumors. Molecular Cancer Therapeutics. 24(10_Supplement). A026–A026.
2.
Rice, William G., Stephen B. Howell, Nasrin Rastgoo, et al.. (2022). Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia. Molecular Cancer Therapeutics. 21(7). 1125–1135. 6 indexed citations
3.
Ohanian, Maro, Martha Arellano, Moshe Levy, et al.. (2021). A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS. Blood. 138(Supplement 1). 3411–3411. 11 indexed citations
4.
Zhang, Lun, et al.. (2021). Pathophysiological roles of myristoylated alanine-rich C-kinase substrate (MARCKS) in hematological malignancies. Biomarker Research. 9(1). 34–34. 12 indexed citations
5.
Tremblay‐LeMay, Rosemarie, et al.. (2020). Role of CD47 in Hematological Malignancies. Journal of Hematology & Oncology. 13(1). 96–96. 114 indexed citations
6.
Zhang, Lun, Nasrin Rastgoo, Jian Wu, et al.. (2020). MARCKS inhibition cooperates with autophagy antagonists to potentiate the effect of standard therapy against drug-resistant multiple myeloma. Cancer Letters. 480. 29–38. 12 indexed citations
7.
Rastgoo, Nasrin, Matthew Thayer, Khalid Benbatoul, et al.. (2020). Abstract 4225: CG-806, a first-in-class FLT3/BTK inhibitor, and venetoclax synergize to inhibit cell proliferation and to induce apoptosis in aggressive B-cell lymphomas. Cancer Research. 80(16_Supplement). 4225–4225. 2 indexed citations
8.
Zhang, Hongying, Nasrin Rastgoo, Khalid Benbatoul, et al.. (2020). Abstract CT239: Early clinical findings from a phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with relapsed or refractory CLL/SLL or non-Hodgkin's lymphomas. Cancer Research. 80(16_Supplement). CT239–CT239. 1 indexed citations
9.
10.
Rastgoo, Nasrin, Jian Wu, Eshetu G. Atenafu, et al.. (2019). Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma. Haematologica. 105(12). 2813–2823. 43 indexed citations
11.
Rastgoo, Nasrin, et al.. (2018). Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS. Leukemia. 32(11). 2471–2482. 63 indexed citations
12.
Tremblay‐LeMay, Rosemarie, Nasrin Rastgoo, & Hong Chang. (2018). Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway. Journal of Hematology & Oncology. 11(1). 46–46. 58 indexed citations
13.
Tremblay‐LeMay, Rosemarie, et al.. (2018). EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies. Biomarker Research. 6(1). 34–34. 42 indexed citations
14.
Rastgoo, Nasrin, Jahangir Abdi, Jian Hou, & Hong Chang. (2017). Role of epigenetics-microRNA axis in drug resistance of multiple myeloma. Journal of Hematology & Oncology. 10(1). 121–121. 47 indexed citations
15.
Abdi, Jahangir, Nasrin Rastgoo, Lihong Li, Wenming Chen, & Hong Chang. (2017). Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis. Journal of Hematology & Oncology. 10(1). 169–169. 48 indexed citations
16.
17.
Rastgoo, Nasrin, et al.. (2011). Green Fluorescent-Conjugated Anti-CEA Single Chain Antibody for the Detection of CEA-Positive Cancer Cells. Hybridoma. 30(3). 229–238. 7 indexed citations
18.
Salmanian, Ali Hatef, et al.. (2009). Isolation of BNYVV Coat Protein-Specific Single Chain Fv from a Mouse Phage Library Antibody. Hybridoma. 28(5). 305–313. 10 indexed citations
19.
20.
Rastgoo, Nasrin, et al.. (2009). Restoring 3′–5′ exonuclease activity of thermophilic Geobacillus DNA polymerase I using site-directed mutagenesis in active site. Journal of Biotechnology. 144(4). 245–252. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qing Tong Breakdown of academic impact, for papers by Karel Fostier Breakdown of academic impact, for papers by Talía Velasco-Hernández Breakdown of academic impact, for papers by Virginia Giuliani Breakdown of academic impact, for papers by Srikanth Talluri Breakdown of academic impact, for papers by Felipe Vences‐Catalán Breakdown of academic impact, for papers by Dazhong Zhuang Breakdown of academic impact, for papers by Margaret Bell Breakdown of academic impact, for papers by Joydeep Bhadury Breakdown of academic impact, for papers by Margherita Ghisi
Rankless by CCL
2026